I-MAB (IMAB) Days Sales Outstanding : 0.00 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Days Sales Outstanding?

I-MAB's average Accounts Receivable for the three months ended in Dec. 2024 was $0.00 Mil. I-MAB's Revenue for the three months ended in Dec. 2024 was $0.00 Mil.

The historical rank and industry rank for I-MAB's Days Sales Outstanding or its related term are showing as below:

During the past 8 years, I-MAB's highest Days Sales Outstanding was 332.54. The lowest was 30.88. And the median was 181.71.

IMAB's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.935
* Ranked among companies with meaningful Days Sales Outstanding only.

I-MAB's Days Sales Outstanding stayed the same from Sep. 2023 (0.00) to Dec. 2024 (0.00).

I-MAB Days Sales Outstanding Historical Data

The historical data trend for I-MAB's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Days Sales Outstanding Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Sales Outstanding

Get a 7-Day Free Trial

30.88

332.54

I-MAB Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Days Sales Outstanding	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of I-MAB's Days Sales Outstanding

For the Biotechnology subindustry, I-MAB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

I-MAB's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where I-MAB's Days Sales Outstanding falls into.

Save Embed

;

Save Embed

;

I-MAB Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

I-MAB's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

	Days Sales Outstanding (A: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

I-MAB's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding (Q: Dec. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2024 )	+	Accounts Receivable (A: Dec. 2024 ))	/	count )	/	Revenue (A: Dec. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

I-MAB (NAS:IMAB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

I-MAB Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of I-MAB's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).